Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agatolimod + Gemcitabine/Cisplatin in Advanced NSCLC
NCT00254904Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Nov 2005
- Primary completion
- Jun 2008
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of agatolimod in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Overall Survival. Started Nov 2005; status: terminated.
02
Drugs
agatolimod
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00254904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254904.